• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Increase the number of Office of Generic Drugs (OGD) meetings with industry to provide guidance

Dictionary: Providing guidance to industry using a variety of mechanisms is intended to assist with the development of high quality, generic drug products by a number of potential manufacturers. Guidance in the form of meetings is especially valuable for developing more complex products such as dry powder inhalers or topical products for which generics are not currently available. FDA’s scientific guidance documents are intended to maximize both industry and OGD resources by minimizing less than optimal product development and applications that cannot be approved.


These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A8
Nov 2009N/A2
Dec 2009N/A0
Jan 2010N/A7
Feb 2010N/A2
Mar 2010N/A0
Apr 2010N/A4
May 2010N/A0
Jun 2010N/A1
Jul 2010N/A1
Aug 2010N/A0
Sep 2010N/A0

FY 2010 Total: 25

Increase the number of presentations to external organizations

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A16
Nov 2009N/A1
Dec 2009N/A0
Jan 2010N/A1
Feb 2010N/A2
Mar 2010N/A5
Apr 2010N/A8
May 2010N/A4
Jun 2010N/A0
Jul 2010N/A0
Aug 2010N/A0
Sep 2010N/A1

FY 2010 Total: 38

Number of guidances initiated

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A1
Nov 2009N/A0
Dec 2009N/A0
Jan 2010N/A0
Feb 2010N/A0
Mar 2010N/A1
Apr 2010N/A0
May 2010N/A0
Jun 2010N/A0
Jul 2010N/A0
Aug 2010N/A0
Sep 2010N/A0

FY 2010 Total: 2

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.